TBPH logo

Theravance Biopharma (TBPH) Cash From Financing

Annual CFF

-$198.93 M
+$559.87 M+73.78%

December 31, 2023

Summary

Performance

1-Year Change

+73.78%

3-Year Change

-175.62%

5-Year Change

-188.34%

15-Year Change

-12112.86%

TBPH Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

6.69%
TBPH annual cash flow from financing activities is higher than 6.69% of companies in Healthcare sector

High & Low

All-time High

$479.23 M
TBPH annual cash flow from financing activities is currently -141.51% below its historical high of $479.23 million

3-Year Low

-$758.81 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
TBPH previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 26, 2025
TBPH next annual earnings announcement is scheduled for Feb 26, 2025

OtherTBPHcash flowmetrics:

Annual CFI

-$32.70 M
TBPH annual cash flow from investing activities is -$32.70 million

Annual CFO

-$27.00 M
TBPH annual cash flow from operations is -$27.00 million

Annual FCF

-$29.48 M
TBPH annual free cash flow is -$29.48 million

Annual CAPEX

$2.49 M
TBPH annual capital expenditures is $2.49 million

Quarterly CFF

-$372.00 K
-$328.00 K-745.45%

September 30, 2024

Summary

Performance

3-Month Change

-745.45%

1-Year Change

+98.82%

3-Year Change

+83.73%

5-Year Change

-150.07%

TBPH Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

24.78%
TBPH quarterly cash flow from financing activities is higher than 24.78% of companies in Healthcare sector

High & Low

All-time High

$332.45 M
TBPH quarterly cash flow from financing activities is currently -100.11% below its historical high of $332.45 million

3-Year Low

-$722.03 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
TBPH previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 26, 2025
TBPH next earnings announcement is scheduled for Feb 26, 2025

OtherTBPHcash flowmetrics:

Quarterly CFI

-$17.40 M
TBPH quarterly cash flow from investing activities is -$17.40 million

Quarterly CFO

-$5.20 M
TBPH quarterly cash flow from operations is -$5.20 million

Quarterly FCF

-$5.21 M
TBPH quarterly free cash flow is -$5.21 million

Quarterly CAPEX

$15.00 K
TBPH quarterly capital expenditures is $15.00 thousand

TTM CFF

-$32.74 M
+$31.03 M+48.66%

September 30, 2024

Summary

Performance

3-Month Change

+48.66%

1-Year Change

+83.93%

3-Year Change

-135.41%

5-Year Change

-112.45%

TBPH TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

11.65%
TBPH TTM cash flow from financing activities is higher than 11.65% of companies in Healthcare sector

High & Low

All-time High

$479.23 M
TBPH TTM cash flow from financing activities is currently -106.83% below its historical high of $479.23 million

3-Year Low

-$894.42 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
TBPH previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 26, 2025
TBPH next earnings announcement is scheduled for Feb 26, 2025

OtherTBPHcash flowmetrics:

TTM CFI

-$4.08 M
TBPH TTM cash flow from investing activities is -$4.08 million

TTM CFO

-$11.49 M
TBPH TTM cash flow from operations is -$11.49 million

TTM FCF

-$12.31 M
TBPH TTM free cash flow is -$12.31 million

TTM CAPEX

$819.00 K
TBPH TTM capital expenditures is $819.00 thousand

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

TBPH Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+73.8%+98.8%+83.9%
3 y3 years-175.6%+83.7%-135.4%
5 y5 years-188.3%-150.1%-112.5%

TBPH Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-316.6%+73.8%-349.7%+100.0%-132.2%+96.3%
5 y5-year-175.6%+73.8%-100.1%+100.0%-112.4%+96.3%
alltimeall time-141.5%+73.8%-100.1%+100.0%-106.8%+96.3%

Theravance Biopharma Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
-$372.00 K(+745.5%)
-$32.74 M(-48.7%)
Jun 2024
-
-$44.00 K(-97.4%)
-$63.77 M(-55.8%)
Mar 2024
-
-$1.72 M(-94.4%)
-$144.41 M(-27.4%)
Dec 2023
-$198.93 M(-73.8%)
-$30.61 M(-2.5%)
-$198.93 M(-2.4%)
Sep 2023
-
-$31.40 M(-61.1%)
-$203.80 M(-77.2%)
Jun 2023
-
-$80.68 M(+43.5%)
-$894.42 M(+9.9%)
Mar 2023
-
-$56.24 M(+58.5%)
-$813.60 M(+7.2%)
Dec 2022
-$758.81 M(-926.0%)
-$35.47 M(-95.1%)
-$758.81 M(+4.9%)
Sep 2022
-
-$722.03 M(<-9900.0%)
-$723.18 M(>+9900.0%)
Jun 2022
-
$140.00 K(-109.7%)
-$3.44 M(-103.4%)
Mar 2022
-
-$1.45 M(-1071.8%)
$101.70 M(+10.7%)
Dec 2021
$91.86 M(-65.1%)
$149.00 K(-106.5%)
$91.86 M(-0.6%)
Sep 2021
-
-$2.29 M(-102.2%)
$92.45 M(-1.4%)
Jun 2021
-
$105.28 M(-1032.7%)
$93.78 M(-1073.3%)
Mar 2021
-
-$11.29 M(-1619.2%)
-$9.63 M(-103.7%)
Dec 2020
$263.08 M(>+9900.0%)
$743.00 K(-177.2%)
$263.08 M(+0.9%)
Sep 2020
-
-$963.00 K(-151.4%)
$260.80 M(-0.3%)
Jun 2020
-
$1.87 M(-99.3%)
$261.63 M(-1.0%)
Mar 2020
-
$261.43 M(<-9900.0%)
$264.16 M(>+9900.0%)
Dec 2019
$1.29 M(-99.4%)
-$1.54 M(+1052.2%)
$1.29 M(-99.4%)
Sep 2019
-
-$134.00 K(-103.0%)
$232.44 M(+0.1%)
Jun 2019
-
$4.40 M(-407.2%)
$232.25 M(+3.0%)
Mar 2019
-
-$1.43 M(-100.6%)
$225.45 M(+0.1%)
Dec 2018
$225.20 M
$229.60 M(<-9900.0%)
$225.20 M(-6068.7%)
DateAnnualQuarterlyTTM
Sep 2018
-
-$322.00 K(-86.6%)
-$3.77 M(-11.0%)
Jun 2018
-
-$2.40 M(+43.0%)
-$4.24 M(-455.7%)
Mar 2018
-
-$1.68 M(-366.2%)
$1.19 M(-28.0%)
Dec 2017
$1.66 M(-99.7%)
$631.00 K(-180.0%)
$1.66 M(-99.5%)
Sep 2017
-
-$789.00 K(-126.0%)
$333.48 M(-0.4%)
Jun 2017
-
$3.03 M(-349.2%)
$334.75 M(-25.9%)
Mar 2017
-
-$1.22 M(-100.4%)
$451.99 M(-5.7%)
Dec 2016
$479.23 M(+489.4%)
$332.45 M(>+9900.0%)
$479.23 M(+138.9%)
Sep 2016
-
$481.00 K(-99.6%)
$200.61 M(+0.3%)
Jun 2016
-
$120.27 M(+362.2%)
$200.05 M(+146.1%)
Mar 2016
-
$26.02 M(-51.7%)
$81.29 M(-0.0%)
Dec 2015
$81.31 M(-78.1%)
$53.84 M(<-9900.0%)
$81.31 M(+197.7%)
Sep 2015
-
-$82.00 K(-105.4%)
$27.31 M(-1.2%)
Jun 2015
-
$1.51 M(-94.2%)
$27.65 M(-92.1%)
Mar 2015
-
$26.04 M(<-9900.0%)
$350.25 M(-5.5%)
Dec 2014
$370.62 M(+199.9%)
-$158.00 K(-160.3%)
$370.62 M(-8.9%)
Sep 2014
-
$262.00 K(-99.9%)
$407.03 M(-7.5%)
Jun 2014
-
$324.10 M(+598.2%)
$439.94 M(+212.3%)
Mar 2014
-
$46.42 M(+28.0%)
$140.88 M(+14.0%)
Dec 2013
$123.59 M(+1.7%)
$36.25 M(+9.3%)
$123.59 M(+41.5%)
Sep 2013
-
$33.17 M(+32.5%)
$87.34 M(+61.2%)
Jun 2013
-
$25.04 M(-14.1%)
$54.17 M(+85.9%)
Mar 2013
-
$29.13 M
$29.13 M
Dec 2012
$121.54 M
-
-

FAQ

  • What is Theravance Biopharma annual cash flow from financing activities?
  • What is the all time high annual CFF for Theravance Biopharma?
  • What is Theravance Biopharma annual CFF year-on-year change?
  • What is Theravance Biopharma quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Theravance Biopharma?
  • What is Theravance Biopharma quarterly CFF year-on-year change?
  • What is Theravance Biopharma TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Theravance Biopharma?
  • What is Theravance Biopharma TTM CFF year-on-year change?

What is Theravance Biopharma annual cash flow from financing activities?

The current annual CFF of TBPH is -$198.93 M

What is the all time high annual CFF for Theravance Biopharma?

Theravance Biopharma all-time high annual cash flow from financing activities is $479.23 M

What is Theravance Biopharma annual CFF year-on-year change?

Over the past year, TBPH annual cash flow from financing activities has changed by +$559.87 M (+73.78%)

What is Theravance Biopharma quarterly cash flow from financing activities?

The current quarterly CFF of TBPH is -$372.00 K

What is the all time high quarterly CFF for Theravance Biopharma?

Theravance Biopharma all-time high quarterly cash flow from financing activities is $332.45 M

What is Theravance Biopharma quarterly CFF year-on-year change?

Over the past year, TBPH quarterly cash flow from financing activities has changed by +$31.03 M (+98.82%)

What is Theravance Biopharma TTM cash flow from financing activities?

The current TTM CFF of TBPH is -$32.74 M

What is the all time high TTM CFF for Theravance Biopharma?

Theravance Biopharma all-time high TTM cash flow from financing activities is $479.23 M

What is Theravance Biopharma TTM CFF year-on-year change?

Over the past year, TBPH TTM cash flow from financing activities has changed by +$171.06 M (+83.93%)